Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer

Wei, Benjie; Shan, Yanhong; Du, Zhaoli; Yin, Chao; Zhang, Qianqian; Li, Haifeng; Zhang, Guirong; Song, Dong Xue; Zuo, Hongbin

doi:10.1007/s12010-022-03946-0

Cited by 5 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study reported by Arteaga's group characterized the molecular profiling of the residual disease of patients with TNBC [43]. The investigators showed an enrichment of basal-like TNBC samples with MCL1 amplifications, PTEN deletions-mutations and JAK2 amplifications; enrichments occurred in genes constituting cell-cycle regulators and PI3K/ mTOR pathway, confirmed consistently in other studies [44][45][46][47]. Potential actionability of the genomic alterations was suggested, to select postneoadjuvant treatments.…”

Section: Molecular and Immunological Characteristic Of The Residual D...supporting

confidence: 54%

Postneoadjuvant treatment for triple-negative breast cancer

Trapani

Ferraro

Giugliano

et al. 2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewTriple-negative breast cancer (TNBC) has been conventionally associated with poor prognosis, as a result of limited therapeutic options. In the early setting, prognosis is informed by clinical–pathological factors; for patients receiving neoadjuvant treatments, pathological complete response (pCR) is the strongest factor. In this review, we mapped the landscape of clinical trials in the postneoadjuvant space, and identified three patterns of clinical trial design.Recent findingsFor patients at higher risk, effective postneoadjuvant treatments are of paramount importance to address a high clinical need. Postneoadjuvant risk-adapted treatments have demonstrated to improve survival in patients at high of recurrence.SummaryPatients at high risk have indication for adjuvant treatment intensification, informed by baseline clinical, pathological or molecular factors (type 1 approach), on the presence, extent and molecular characteristics of the residual disease at the time of surgery (type 2) or on risk factors assessed in the postsurgical setting (type 3), for example, circulating tumour DNA. Most of the past trials were based on type 2 approaches, for example, with capecitabine and Olaparib. Few trials were based on a type 1 approach, notably pembrolizumab for early TNBC. The clinical validity of type 3 approaches is under investigation in several ongoing trials.

show abstract

Section: Molecular and Immunological Characteristic Of The Residual D...supporting

confidence: 54%

Postneoadjuvant treatment for triple-negative breast cancer

Trapani

Ferraro

Giugliano

et al. 2022

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…The encoded proteins are important for damage sensing and DNA binding, and show a preference for single-stranded DNA. In addition, a number of studies have found that polymorphisms of FEN1 and XPC genes are associated with the risk of various diseases (Guan et al, 2022;Wei et al, 2022;Datkhile et al, 2022;Zhao et al, 2018). Based on this, we introduced the polymorphisms of FEN1 and XPC genes into this study to further explore the relationship between the polymorphisms of FEN1 and XPC genes and the DNA damage level of Cytb gene.…”

Section: Discussionmentioning

confidence: 96%

Polymorphism of FEN1 Gene is Associated with DNA Damage of Cytb Gene in Arsenic-Exposed Workers

Zhao

Jiang

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: To explore the relationship between Polymorphism of FEN1 Gene and DNA Damage of Cytb Gene in Arsenic-Exposed Workers. Methods: The content of arsenide in urine of 79 arsenic-exposed workers and 24 agricultural workers was detected by an atomic absorption spectrophotometer. The DNA damage level of Cytb gene and the polymorphism of FEN1 gene in peripheral blood were detected by polymerase chain reaction. Results: The increased exposure to arsenic caused DNA damage of Cytb gene, resulting in an increase in the content of arsenide in urine and hypomethylation of arsenic metabolism. Meanwhile, there was a potential positive correlation between the FEN1 rs174538 AA or GA+AA allele and the DNA damage level of Cytb gene. Conclusions: The DNA damage of Cytb gene caused by arsenic exposure is related to FEN1 gene polymorphism, the content of arsenide in urine and the level of arsenic methylation metabolism.

show abstract

Development of a Competitive Chemiluminescent Assay for Quantitative Determination of TP53 Fusion Protein Using Reagent Strips

Wang,

He,

2024

Appl Biochem Biotechnol

View full text Add to dashboard Cite

Recent studies have shown that almost half of all cancers occur due to DNA damage. For the early diagnosis of cancer, a highly sensitized and swift identi cation for TP53 is needed since the corresponding TP53 protein is effectively recognized as "the guardian of the genome." To improve the detection sensitivity, numerous analytical methods were previously used for the determination of the TP53 protein, including denaturing high-performance liquid chromatography and enzyme-linked immunosorbent assay (ELISA). Currently, immunochromatographic tests (ICTS) that are simple to use, stable over time, and show low interference are regarded as valuable tools for the quick screening of food and environmental monitoring along with clinical diagnosis. ICTS often have limited sensitivity even if a variety of novel reporters possessing optimum photostability and improved brightness are used as the signal-intensity reporters. Compared with N-(4-aminobutyl)-N-(ethylisoluminol) or luminol, a novel luminescent probe, 2',6'-diMethyl-4'-(N-succiniMidyloxycarbonyl) phenyl-10-sulfopropylacridiniuM-9carboxylate (NSP-DMAE-NHS) has achieved a much higher e ciency, improvement in the biosensor's performance, and ampli cation of the signal without causing any damage to the biomolecule in terms of its biochemical activity. In this study, the reagent strip method was initially used to detect TP53 fusion protein by combining the advantages of NSP-DMAE-NHS and immunochromatography. In our experiment, the control and study lines on the strips were immobilized through HRP-conjugated goat antirabbit IgG and TP53 antigen, respectively. The optimized concentration of the anti-TP53 antibody-NSP-DMAE-NHS immunoconjugates was then added to the TP53 antigen samples. After, the test strips were inserted and left in the aforementioned buffer solution for an additional 20 minutes. Finally, a lab made luminous measurement device was used to analyze the corresponding control and study lines on the strips. Under optimized conditions, this method was found to be ultrasensitive, with a wide range of linear responses from 0.0008 ng mL -1 to 1 µg mL -1 and a limit of detection of 0.0008 ng mL -1 (0.013 pM). Thus, a novel competitive chemiluminescent assay based on reagent strips was established for the determination of the TP53 fusion proteins. The strategy has potential applications for ultrasensitive detection in the early diagnosis of cancer.

show abstract

Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer

Cited by 5 publications

References 32 publications

Postneoadjuvant treatment for triple-negative breast cancer

Postneoadjuvant treatment for triple-negative breast cancer

Polymorphism of FEN1 Gene is Associated with DNA Damage of Cytb Gene in Arsenic-Exposed Workers

Development of a Competitive Chemiluminescent Assay for Quantitative Determination of TP53 Fusion Protein Using Reagent Strips

Contact Info

Product

Resources

About